Foghorn Therapeutics (FHTX) Proxy filing summary

Executive summary

• Annual meeting scheduled for June 24, 2026, to be held virtually for stockholders of record as of April 27, 2026.

• Proxy materials, including the Notice of Meeting, Proxy Statement, and Annual Report on Form 10-K, are available online, with paper copies available upon request.

Voting matters and shareholder proposals

• Election of three Class III directors for a three-year term: Douglas Cole, M.D., Balkrishan (Simba) Gill, Ph.D., and B. Lynne Parshall.

• Ratification of Deloitte & Touche LLP as the independent registered public accounting firm for the fiscal year ending December 31, 2026.

• Advisory vote to approve the compensation of named executive officers.

• Advisory vote on the frequency of future advisory votes on executive compensation, with the board recommending a 1-year frequency.

Board of directors and corporate governance

• Board recommends voting FOR all director nominees and FOR all proposals, including a 1-year frequency for say-on-pay votes.